ArticleBlood research2026

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.

Yun-Tzu Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.